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Abstract
Background: The number of people affected by Parkinson’s disease (PD) is increasing in the United Kingdom driven
by population ageing. The treatment of the disease is complex, resource intensive and currently there is no known
cure to PD. The National Health Service (NHS), the public organisation delivering healthcare in the UK, is under financial
pressures. There is a need to find innovative ways to improve the operational and financial performance of treating PD
patients. The use of community services is a new and promising way of providing treatment and care to PD patients at
reduced cost than hospital care. The aim of this study is to evaluate the potential operational and financial
benefits, which could be achieved through increased integration of community services in the delivery of
treatment and care to PD patients in the UK without compromising care quality.
Methods: A Discrete Event Simulation model was developed to represent the PD care structure including
patients’ pathways, treatment modes, and the mix of resources required to treat PD patients. The model
was parametrised with data from a large NHS Trust in the UK and validated using information from the
same trust. Four possible scenarios involving increased use of community services were simulated on the
model.
Results: Shifting more patients with PD from hospital treatment to community services will reduce the number of visits
of PD patients to hospitals by about 25% and the number of PD doctors and nurses required to treat these patients by
around 32%. Hospital based treatment costs overall should decrease by 26% leading to overall savings of 10% in the total
cost of treating PD patients.
Conclusions: The simulation model was useful in predicting the effects of increased use of community services on the
performance of PD care delivery. Treatment policies need to reflect upon and formalise the use of community services
and integrate these better in PD care. The advantages of community services need to be effectively shared
with PD patients and carers to help inform management choices and care plans.
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Background
Neurodegenerative conditions and motor neurone affecting
cognitive and physical ability have life changing impact on
individuals, families and carers. Medical interventions are
of limited benefit for these progressive illnesses if social care
and support for managing daily activities is lacking.
Fundamental to the management of such conditions is
the coordination of care across different health and
social care sectors. From a health systems perspective,
models of integrated and efficient service delivery and
care are required particularly in the context of aging
populations; a challenge particularly in high income
countries. Impact extends across the healthcare economy
(primary, community, secondary and tertiary care) as well
as to other public services including transport, employ-
ment and housing needs [1]. For long-term progressive
conditions, key questions arising are which treatment
pathway? and where? to achieve the best outcome for
patients and healthcare providers and carers. To answer
these questions we focus on one particular condition,
Parkinson’s disease (PD) in a country where the popula-
tion age profile is changing, the United Kingdom (UK).
PD is the second common chronic neurodegenerative
condition in older people especially beyond the age of
sixty [2, 3]. The most common early symptoms of the
disease are problems with movement and this includes
tremor, stiffness, slowness, and paucity of movement [4].
As the disease progresses, additional non-motor symp-
toms such as depression, psychotic symptoms, dementia,
sleep disturbance, falls, and autonomic disturbances be-
come more common adding to the burden of the disease
and its effects on patients and those involved in their
treatment and care. The late phases of the disease are
generally characterised by increased motor complica-
tions, disability, and mortality [5].
PD is a challenging disease from a clinical perspective as
it affects older adults who may also be suffering from
other conditions. There is difficulty in diagnosis especially
in early stages, the condition is associated with a wide
range of symptoms, is progressive and there is currently
no cure for the disease. As a result, the treatment and
management of PD is complex and resource intensive due
to the involvement of a multidisciplinary team and several
services in its management. The complexity is increased
by the fact that the disease does not just affect the patient,
but the effects extend to families, employers, and a wide
range of public services [1, 5].
The disease progresses over four phases and these im-
pact directly on the treatment provided to patients [6].
The Diagnosis phase reflects the initial stage when a
patient is suffering from PD with symptoms and signs,
but there is no formal confirmation that the patient has
PD. Once diagnostic tests are conducted and PD is con-
firmed, the patient moves to the Maintenance phase.
Depending on the patient status, either no treatment is
provided at this phase or treatment involving small
doses of one or two drugs is commenced. As there is no
cure for PD, the aim of the treatment is to slow the pro-
gression of the disease so that patient quality of life is
not affected. As the symptoms worsen and more func-
tions of the body are affected, the patient enters the
Complex phase in which the number of drugs and their
doses are increased and, in some cases, neurosurgery is
performed. The final phase, known as Palliative, is char-
acterised by high risks of physical and mental disabilities
and significant threats to life.
The treatment modes for PD include inpatient, out-
patient, and community care and require a range of clinical
specialists [7]. Inpatient care involves drug treatment and
surgery in hospitals. Outpatient care provides drug treat-
ment and, in some instances, specialised therapies such as
Physiotherapy, Psychiatry, Occupational Therapy, and
Speech and Language Therapy. This care takes place mostly
in General Practitioners (GPs) clinics and sometimes in
hospitals. Community care, which focuses on specialised
therapies, is provided in local care units, under Community
Services, with the support of local pharmacies and social
services.
The UK population is aging and, therefore, it is expected
that the number of people who will be diagnosed with PD
will increase in the future. In 2012, the number of people
aged 65 years and over was 10.84 million from which 1.44
million were aged 85 years and over. The number of
people aged 65 years and over is expected to rise to 17.79
million from which 3.64 million will be aged 85 years and
over in 2037 [8]. The latest available data suggest that the
number of individuals living with PD in the UK is
127,000, corresponding to a prevalence rate of 27.4/10,000
[9]. This number is expected to rise in line with the popu-
lation ageing trend and to reach 165,000 in 2020 [9].
Healthcare in the UK is delivered free of charge, at the
point of care, by a public organisation known as the “Na-
tional Health Service (NHS)”. Current evidence suggests
that the NHS is struggling to cope with the demand for
PD treatment and care. A National Audit Office report
found that although access for patients with neurological
conditions including PD to health services improved since
2007, spending increased by 38% in real terms and the
quality of care declined during the same period [1]. Just
over half (66%) of GP referrals meet the National Institute
for Health and Care Excellence (NICE) guidelines of a
specialist appointment within 6 weeks and 14% of patients
are readmitted within 28 days of discharge. Recent work
has shown that less than a quarter of PD patients (22%)
have a personal care plan [10].
This situation is alarming especially as the NHS is faced
with additional pressures stemming from ever increasing
resource and capacity constraints and the need to improve
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operational and cost efficiency. The NHS has a target of
making a net saving of £20 Billion over the coming 4–5
years [11]. However, given its sheer size and complexity
(the NHS employs more than 1.6 million people and deals
with more than 1 million patients every 36 h [12]), the
challenges are significant.
In this new reality of “doing more with less”, it is
necessary to identify areas where efficiency gains can be
made. This is challenging in the case of PD given the
wide range of treatment modes and therapies required
by patients, the different settings where the treatment is
provided, and the need to customize the treatment at an
individual patient level depending on their disease stage,
severity of the symptoms and support structures avail-
able. For example, some patients may be seen by a PD
doctor or by a PD nurse monthly, quarterly or every
6 months, for single or multiple therapies. A better un-
derstanding of the different possible configurations to
deliver treatment and care to PD patients and the evalu-
ation of the operational and cost performance of these
configurations is required so that the most efficient ones
are identified.
Treatment configurations involving increased use of
community services could yield significant efficiency gains.
Treating more patients in community services may reduce
unnecessary hospital admissions, the need for consulta-
tions with PD doctors and nurses, and facilitate the earlier
discharge if admitted [5]. Treating patients in community
services has a significant cost advantage over treatment in
hospitals. The average cost to treat a PD patient admitted
to inpatient care as an emergency admission is £2,133
(based on an average length of stay of 6.3 days) and the
average cost of a PD doctor visit is around £145. In con-
trast, the costs associated with community services are in
the region of £38 to £98 (e.g. physiotherapy £38, occupa-
tional therapy £56 and speech and language therapy £98)
[13]. The additional benefit is that community services
improve patients’ understanding of their own disease jour-
ney and empower them to better self-manage their condi-
tion. This is why they have been welcomed by patients [5].
The lack of research to evaluate operational and cost
performance of possible configurations is surprising
given the potential efficiency gains which could be
achieved through increased deployment of community
services. The vast majority of research, with regard to
PD performance evaluation, has focused on quality of
life of patients and the effects of PD symptoms and
social factors on the physical and psychological well-
being of patients [14–17]. The literature covering the
evaluation of PD care configurations includes only a
2011 report by the UK National Audit Office, which
recommends the use of community services and
recently published research providing some evidence
that the use of community services reduces PD
doctors and nurses’ activity levels [7]. This is a clear
research gap, which warrants further investigation.
The aims of this study are therefore: First, to develop a
Discrete Event Simulation (DES) model, which captures
the PD treatment pathways and service configurations
including community services; Second, to determine pos-
sible and realistic policies, which could be implemented
with regard to an increased use of community services and
how these would affect hospital based treatment; Third, to
evaluate the impact of the implementation of these policies
on a number of operational and cost performance indica-
tors relevant to the delivery of PD treatment and care. This
should provide an indication of the feasibility and scale of
efficiency improvement, which could be achieved by
shifting more PD patients to community services and
allow health managers to make informed decisions with
regard to the best ways to reconfigure the PD care
delivery system in the UK.
Methods
We developed a Discrete Event Simulation (DES) model
[18–20] to portray the structure and configuration of the
PD treatment and care system including patients’ path-
ways, disease phases, treatment modes, and the resources
required to provide treatment and care. DES is appro-
priate in the context of this research as it enables the
modelling of patients at the individual level including
disease evolution over time and how a patient moves
through the different parts of the care system. DES
makes it possible to represent different patient general
attributes such as age and gender and clinical specific
attributes such as disease phase and treatment mode.
As time progresses, patients’ attributes are altered to
reflect changes in their status. This allows the tracking
of patients as they evolve in the care system including
the events they experience at different points of time.
DES provides the flexibility to incorporate capacity and
resource constraints explicitly, and to capture the
resource allocation policies and priority rules where
entities compete for limited resources. This feature is
extremely important in health contexts, as clinical
activities such as diagnosis, treatment, and consulta-
tions require a mix of specialised resources (doctors,
nurses, beds, operating theatres, and so on) and these
resources are, in most cases, not sufficient to meet the
required level of demand.
DES has been applied to health management since the
1990s driven by the increased complexity of health care
systems, the considerable advancements in DES software
capabilities, ease of use, and the shift to more evidence
based decision making in the health sector [21–24]. The
increased popularity of DES in health management is
reflected in the literature, which show an upward trend
in terms of the number of DES applications and the
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areas covered by these applications [23, 25]. Examples of
these applications include modelling of patient flows in
hospitals and accident and emergency departments in
particular [26, 27], reconfiguration of care delivery ser-
vices and capacity planning and management in the
health sector [28–31], cost effectiveness of treatment proce-
dures [32–35], patients’ compliance with screening proce-
dures [36], and policies to prevent transmission of diseases
[37].
Simulation Model Development
The model was developed in collaboration with health
care professionals and potential end-users and its building
process started with a meeting with the National Com-
mittee of the Parkinson’s Disease Nurse Specialist Asso-
ciation (PDNSA) in late 2012. Six PD specialist nurses
were involved and provided detailed information re-
garding patients’ pathways and treatment procedures,
the services and resources required in the diagnosis and
treatment of PD, and the rules and policies associated with
the management of the patients. Semi structured inter-
views were conducted with the nurses and led to an initial
mapping of the PD patients’ pathway structure. This map
was further developed and refined through structured
interviews with members of the PDSNA national com-
mittee, who checked that the initial map reflected the
patients’ pathways and suggested corrections where
gaps were identified.
The interviews indicated that the first point of contact of
a patient with the PD care system is a visit to a PD out-
patient clinic following referral from a General Practitioner
(GP), Accident and Emergency (A&E) units, outpatient
department, or a hospital department. Diagnostic tests are
carried out, and, if PD is confirmed, patients are categorised
into one of the disease phases (Diagnosis, Maintenance,
Complex or Palliative) and treatment commences. The
treatment is supervised by a PD doctor and takes the form
of a referral to surgery (in a small number of cases), treat-
ment via drugs, special therapies (eg Physiotherapy, Lan-
guage and Speech Therapy, Occupational Therapy) in
community services, or a combination of these treatment
modes (for example treatment via drugs and special ther-
apies) (See Fig. 1) The PD specialist overseeing the treat-
ment of each individual patient is supported by a PD
specialist nurse, who plays a critical role in the manage-
ment of the PD patient and determination of their treat-
ment needs.
As there is no known cure for PD, the treatment is a
continuous process over time and the patient remains in
treatment indefinitely. Patients meet their allocated PD
doctor and PD nurse on a regular basis and the frequency
of these meetings depends on the disease phase of the
patient. The treatment guidelines indicate that patients in
the Diagnosis, Maintenance, Complex and Palliative
phases meet with the PD doctor and PD nurse 2, 4, 5 and
6 times a year respectively. In these meetings, disease pro-
gression is evaluated and decisions made about changes to
drug combinations. Requirements regarding the use of
primary care or community services for special therapies
are also determined in these meetings depending on the
medical state of the patient.
One important aspect of the meetings between the PD
doctor and the patient is the assessment of the medical
status of the patient and the decision to keep or change
the disease phase of the patient. As described earlier, once
a patient is formally diagnosed with PD, that patient is al-
located to one of the four phases of the disease (Diagnosis,
Diagnosis, Maintenance, Complex, Palliative) as this deter-
mines the treatment process and the frequency of the
patient’s meetings with the PD doctor and PD nurse. The
decision to keep or alter the patient’s phase will, conse-
quently, have important implications for the treatment
and management of patients as it affects the level of re-
sources required for the treatment and the needs in terms
of the special therapies prescribed for the patient.
The information generated in the interviews regarding
the PD patients’ pathways (shown in Fig. 1) and how the
patients are treated and managed were entered in a
simulation model built using the software SIMUL8
(www.simul8.com). The model represented the four
different sources (GPs, A&E units, outpatient depart-
ment, hospital department), which bring patients to the
PD care system, progression through different disease
phases (Diagnosis, Maintenance, Complex, and Palliative),
treatment modes, the mix of resources required for the
treatment, and the special therapies provided in commu-
nity services (see Fig. 2 for a snapshot of the SIMUL8
model).
As the model is aimed for decision makers, a friendly
and easy to use interface was added to the SIMUL8
model. The interface is animated and allows users to test
policies regarding changes to demand levels, patient
pathways, allocation of resources, and disease progres-
sion (See Fig. 3). These policies are represented in the
form of scenarios, which the decision makers could
input on the interface and then run the model. Once a
scenario run is completed, the model generates a results
summary on the key performance indicators of interest
to decision makers, which are also shown on the model
interface. In addition, the model generates a complete
set of results which can be exported to an Excel spread-
sheet to enable more detailed analysis.
Model parameters and validation
Several sources of information were used to estimate
the values of the parameters entered in the model (see
Additional file 1: Table S7). The NHS English Hospital
Episodes Statistics (HES) data set (the biggest and most
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Fig. 2 SIMUL8 snapshot of the diagnosis process for Parkinson’s disease patients
Fig. 1 Structure of the Parkinson’s disease patients’ pathway. Adapted from: Demir et al. 2015 [7]
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comprehensive official health statistics database in the
UK) and interviews with PD doctors and nurses were
the sources for parameters regarding origin of referrals,
PD progression and treatment, and provision of com-
munity services.
Given that PD treatment in the UK is decentralised
and entities, known as NHS Trusts, are responsible for
providing care at a regional level, the parameters related
to the number of patients and treatment modes were
estimated from one big NHS Trust, which provides a full
set of treatment modes including special therapies in
community services. In this Trust, the breakdown of
new PD patients by source of referral is 75%, 15%, 5%,
and 5% for GP, A&E, outpatients, and other hospital
department respectively. The distribution of patients by
disease stage category is mostly constant at 10% Diagno-
sis, 60% Maintenance, 25% Complex and 5% Palliative.
Visits to PD doctors occur once a year in the Diagnosis
phase, 2 to 3 times a year in the Maintenance phase, and
3 to 4 times a year in the Complex and Palliative phases.
Patients are seen 2 to 4 times a year by a PD nurse
except in the Palliative stage where a customised care
plan is designed and patients are seen by a PD nurse
once a month.
Information regarding the use of community services is
scarce and mostly unrecorded, so the research team relied
on the extensive experience of PD nurses to estimate the
parameters related to these services. Following interviews,
we determined the percentage of patients referred to com-
munity services including those using a single specialised
therapy (eg physiotherapy) or a combination of therapies
(eg speech and language therapy and occupational
therapy). The number of visits per year to community
services including visits to single or combination of
specialised therapies and the community services therapy
specialists required in these visits were also determined
from the interviews. The breakdown of patients using the
different types of therapies in the Trust from which the
data was collected was confirmed by senior PD doctors
and nurses to be, on average, equal to 45% for physio-
therapy, 42.5% for speech and language therapy, 35%
for occupational therapy, 22.5% for psychiatry services,
7.5% for dietician, and 7.5% for palliative care.
The unit costs associated with the different modes of
treatment (hospital, outpatient, community services)
were determined using the Healthcare Resource Group
(HRG) code, which provide standardised and reference
costs for the treatment of different diseases and clinical
conditions in the UK. The HRG codes and their associ-
ated costs are publicly available on the UK Department
of Health website [13]. These codes enabled us to estimate
the treatment costs for the different treatment modes
including those related to the provision of specialised
therapies in community services. Extra costs were included
to reflect instances of unexpectedly long stay in hospitals or
additional treatments and tests. The number of staff avail-
able and their salaries were determined from interviews.
The list of data entered in the model is presented is
included in an additional file with this paper.
The model was put to validation tests to ensure that it
can be confidently used to simulate alternative scenarios
regarding the treatment procedures of PD patients and
determine the most appropriate policies out of the simu-
lation results. The validation tests covered two aspects:
(i) the model’s ability to replicate historical observations
and (ii) the extent to which the model was a correct
representation of the PD care system (face validity). Data
representing the current situation in the selected Trust
was entered into the model and then run for a period of
3 years and the results generated by the model were
compared to those taken from the Trust data. The
model results were very close to those observed in the
Fig. 3 The Parkinson’s disease simulation model user interface
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real world on a number of variables for which real world
data were available. A summary of the simulation and
real world results for this validation test are presented in
Table 1.
Face validity was performed by showing the PD care
system map and the simulation model to each nurse in-
dividually and then to all nurses in a group workshop.
The model structure was confirmed to be highly repre-
sentative of the real world PD care system by all nurses.
The engagement of the nurses and their continuous
involvement and feedback was instrumental in achieving
face validity for the model.
Results
In addition to building the DES model, this research has
two additional aims, which are (i) to determine the pos-
sible and realistic policies, which could be implemented
with regard to an increased use of community services
in the treatment of PD patients and (ii) to evaluate the
impact of the implementation of these policies on a
number of operational and cost performance indicators
relevant to the delivery of PD treatment and care. Following
extensive discussions with decision makers and experienced
PD doctors and nurses, four possible scenarios were deter-
mined and selected for simulation on the model. These sce-
narios are as follows:
 Scenario 1: Low increase in community services.
Under this scenario, 10% more patients will be
shifted to treatment in community services.
 Scenario 2: Medium increase in community services.
Under this scenario, 20% more patients will be
shifted to treatment in community services.
 Scenario 3: High increase in community services.
Under this scenario, 40% more patients will be
shifted to treatment in community services.
 Scenario 4: Very high increase in community services.
Under this scenario, 50% more patients will be
shifted to treatment in community services.
Following the selection of scenarios, further discus-
sions were carried out with the decision makers to deter-
mine the most appropriate indicators, which could be
used to evaluate the operational and cost performance
of the different PD treatment configurations reflected by
the scenarios. These indicators were divided into three
categories: (i) Level of Activity (ii) Resources Require-
ments and (iii) Cost of Care. The full list of performance
indicators is presented in Table 2.
To achieve robustness of the results, each scenario was
run 100 times (using different random numbers each
time) for a period of three years with a “warm up” period
of 1 year. Results were collected on the performance indi-
cators for the four scenarios. An analysis of these results
suggests the following
 Level of Activity: The results indicate that the policy
to shift more treatment activities to community
services will significantly ease the workload of
hospital based staff (See Table 3). The expected
number of visits to hospitals decreases steadily
from 18582 visits under the baseline scenario to
13889 visits under scenario 4. This trend becomes
steeper as the fraction of patients treated in
community services goes up (See Fig. 4). Starting
from the baseline scenario, the percentage decline
in the expected number of visits to hospitals is
7%, 10%, and 17% under scenarios 1, 2, and 3
respectively and reaches a maximum value of 25%
under scenario 4.The impact of the policy on the
number of visits to community services therapies
is much more important. The expected number of
these visits should increase slightly under scenario 1
(by approximately 4% from 11910 to 12397 visits)
and then the rate of increase will become more
significant at 14% and 33% under scenarios 2 and 3
respectively. However, for scenario 4, the increase
in the expected number of visits becomes extremely
sharp with a total of 22211 visits, which is
equivalent to an 86% increase compared to the
baseline scenario (See Fig. 5).
 Resource Requirements: The level of hospital
resources, expressed in terms of the total
number of Full Time Equivalent (FTEs) for
hospital doctors and nurses, required to treat
PD patients should go down as more patients
Table 1 Simulation and real world results for model validation
Performance Indicator Simulation Results Mean
95% (LCI, UCI)
Real World Results Difference (in Percentage)
PD doctors’ visits 8225 (7732, 8801) 8061 2% (−4%, 8%)
PD nurses visits 10357 (10046,10771) 10875 −5% (−8%, −1%)
PD doctors service hours 8225 (7978, 8554) 8061 2% (−1%, 5%)
PD nurses service hours 10357 (10150, 10978) 10875 −5% (−7%, 1%)
PD doctors total FTEs 1.07 (0.995, 1.123) 1.04 3% (−4%, 7%)
PD nurses total FTEs 3.4 (3.230, 3.502) 3.57 −5% (−10%, −2%)
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are treated in community services rather than
in hospitals (See Table 4). The decrease in the
number of required FTEs becomes more important
as higher fractions of patients are directed to
community services. Specifically, the percentage
reduction in FTEs will be 7% and 9% under
scenarios 1 and 2 respectively before increasing to
16% under scenario 3 and then doubling to 32%
under scenario 4.
 Treatment Costs: The results regarding the expected
hospital costs, community services costs, and total
PD treatment costs are presented in Tables 5
and 6, and Fig. 6. These results show that hospital
treatment costs should decline as policies regarding a
higher use of community services are implemented.
The rate of the decline becomes more important as
higher fractions of patients are treated in community
services. The hospital costs under the baseline
scenario are £3,363,050 and these are expected
to go down to £3,126,780 and £3,007,710 that is
a percentage decrease of 7% and 11% for scenarios 1
and 2 respectively. With regard to scenarios 3 and 4,
the decrease in the hospital costs is more important at
£2,762,790 and 2,494,460, which is equivalent to a
percentage decrease of 18% and 26%.The trend of the
community services costs is similar to that of the
number of visits to community services. As more
patients are directed towards these services, their
associated treatment costs go up by 4% to £755,434
under scenario 1, 14% to £824,044 under scenario 2,
and 33% to £961,398 under scenarios 3 from £725,954
under the baseline scenario. This upward trend
becomes substantially higher for scenario 4 as they
reach £1,356,124, which is equivalent to an 86%
increase compared to the baseline scenario.With
regard to the total PD treatment costs, which
includes both the hospital costs and the community
services costs, adoption of policies to shift a higher
number of patients to treatment in community
services should lead to reduction in the total PD
treatment costs. These saving are made possible as the
decrease in hospital costs offset the increase in that of
the community services leading to net gains with
regard to total PD treatment costs. It is, however,
interesting to notice that total PD treatment costs
are on a steady decreasing pattern reaching their
minimum under scenario 3. The pattern is then
reversed when considering scenario 4. Compared
to the baseline scenario, the percentage decrease in
total PD treatment costs is 5%, 6.3%, and 9% under
scenarios 1, 2, and 3 respectively. This percentage
gain in total PD treatment costs is then reduced
to only 5.8% under scenario 4 as these costs raise
again to reach a level higher than that of scenarios
2 and 3 and close to that of scenario 1.
Discussion
The study indicates that adoption of Community Ser-
vices could lead to positive outcomes in terms of lower
Table 2 Definition of the performance indicators
Performance
Indicator
Definition
Level of Activity
PD doctors’ visits Number of consultations of PD patients
with doctors in hospitals
PD nurses visits Number of consultations of PD patients
with nurses in hospitals
Physiotherapy visits Number of consultations to provide
Physiotherapy to PD patients
SLT therapy visits Number of consultations to provide SLT
therapy to PD patients
Psychiatry visits Number of consultations to provide
Psychiatry therapy to PD patients
Occupational
therapy visits
Number of consultations to provide
Occupational therapy to PD patients
Palliative care visits Number of consultations to provide
Palliative care therapy to PD patients
Dietician visits Number of consultations to provide
Dietician therapy to PD patients
Resource Requirements
PD Doctors service
hours
Number of PD doctors working hours
required to provide treatment to patients
PD nurses service
hours
Number of PD nurses working hours
required to provide treatment to patients
PD Doctors Total
FTEs
Number of Full Time Equivalent (FTEs) of
PD doctors required to provide treatment
to patients
PD Nurses Total
FTEs
Number of Full Time Equivalent (FTEs) of
PD nurses required to provide treatment
to patients
Treatment Costs
PD Doctors cost Total PD doctors costs required to treat
patients in hospitals
PD Nurses cost Total PD nurses costs required to treat
patients in hospitals
Physiotherapy costs Total costs required to provide
Physiotherapy to PD patients
SLT costs Total costs required to provide SLT to
PD patients
Psychiatry costs Total costs required to provide Psychiatry
therapy to PD patients
Occupational therapy
costs
Total costs required to provide Occupational
therapy to PD patients
Palliative care costs Total costs required to provide Palliative care
therapy to PD patients
Dietician costs Total costs required to provide Dietician
therapy to PD patients
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total PD treatment costs, decrease in the workload and
activity levels of clinical staff in hospitals, and reduced
requirements in terms of hospital resources and clinical
headcount. This is helpful to policy makers who are re-
quired to provide treatment and high quality care for an
increased number of PD patients in the context of re-
duced public funding for health. As more resources are
freed in hospitals, this opens up the possibility to absorb
the increasing demand for PD treatment and, conse-
quently, reduce the time PD patients need to wait before
commencement of treatment.
This positive impact within hospitals, however, must
be viewed in conjunction with the increased costs and
workload that shifting patients to community services
brings. Successful implementation of any such policy in-
volving shifting across sectors must be supported by
careful processes of capacity management in community
services, work-force planning and training programs. Re-
vised procedures of commissioning and purchasing of ser-
vices for PD patients must be in parallel with effective
integration between health and social services. It is critical
for policy makers to adopt a holistic approach to the man-
agement and treatment of PD patients. Focusing on the
benefits of the policy on one element delivering the
treatment (hospitals) and ignoring the spill over effects
on the other element (community services) may lead to
the opposite of what the policy is intended to achieve.
From a scale perspective, the overall performance
gains, which could be achieved at the UK level could be
important. The results reported in this study are for a
single Trust only, but given that there are more than 350
NHS Trusts in the UK [8], the potential magnitude of
Fig. 4 Expected number of hospital visits
Table 3 Average, 95% lower and upper CI results for the number of visits to PD doctors and nurses
Performance Indicator Baseline Scenario 1: Low
use of CS
Scenario 2: Medium
Use of CS
Scenario 3: High
Use of CS
Scenario 4: Very High
Use of CS
PD doctors’ visits 8225 (7732, 8801) 7494 (7194, 7944) 7158 (6872, 7516) 6537 (6145, 6798) 5873 (5638, 6108)
PD nurses visits 10357 (10046,10771) 9854 (9263,10248) 9553 (8980, 10126) 8831 (8301, 9449) 8016 (7695, 8417)
Total Hospital Visits 18582 (17778, 19572) 17348 (16457, 18192) 16711 (15852, 17642) 15368 (14446, 16247) 13889 (13333, 14525)
Physiotherapy visits 3554 (3341, 3767) 3700 (3552, 3922) 4036 (3915, 4319) 4708 (4567, 5038) 6755 (6552, 7228)
SLT visits 3357 (3256, 3592) 3494 (3389, 3704) 3811 (3620, 4002) 4447 (4314, 4714) 6379 (6124, 6762)
Psychiatry visits 1776 (1723, 1847) 1850 (1739, 1943) 2019 (1938, 2120) 2355 (2214, 2449) 3378 (3175, 3581)
Occupational
therapy visits
2335 (2265, 2428) 2420 (2323, 2589) 2640 (2561, 2746) 3079 (2987, 3264) 4150 (3901, 4441)
Palliative care visits 454 (440, 481) 477 (453, 496) 519 (498, 555) 606 (570, 648) 731 (702, 760)
Dietician visits 434 (421, 451) 456 (442, 488) 496 (481, 531) 579 (562, 614) 818 (777, 859)
Total Community
Services Visits
11910 (11446, 12566) 12397 (11898, 13142) 13521 (13013, 14273) 15774 (15214, 16727) 22211 (21231, 23631)
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total savings in PD treatment costs is significant. As the
NHS is in financial deficit (£471 Million in the financial
year 2014/15), the important potential cost reductions
resulting from a wider use of Community Services can
contribute toward much needed sustainable solutions.
The results also suggest that there is an “optimal”
fraction of PD patients, which could be shifted to Com-
munity Services. The overall PD treatment costs have a
decreasing pattern up to the scenario where the shift is
at a level of 40%; but total costs increase beyond this
percentage. This finding has important implications
with regard to scaling of Community Services and the
best allocation of patients between the hospital and
Community Services settings.
In addition to the benefits from the care delivery per-
spective, there is strong evidence that patients find com-
munity services a friendlier environment and where staff
are more able to deliver tailored care accounting for per-
sonal needs and circumstances of patients [6]. This “hu-
man” aspect has been highlighted by the advocates of a
wider use of these services as positive psychological im-
pact of treatment in community services is as important as
the medical treatment itself. This is especially important for
those patients facing social exclusion, which can
exacerbate some PD symptoms (such as depression and
dementia). As such, community services can play an
important role in reversing PD patients’ low satisfaction
with quality of care and their complaints about the lack
of attention towards their psychological welfare.
The importance of community services in the treatment
and management of patients with PD was highlighted in
policy documents and treatment delivery framework
about a decade ago [5, 38]. However, the acknowledgment
of their important role gained momentum in recent years
due to increased demand and the pressures to deliver effi-
cient and high quality care to PD patients [39, 40]. The
results of this research are in line with this renewed policy
direction and add to the evidence that Community
Services can be an important element of an innovative PD
care delivery model. Making such a model successful,
however, requires an alignment between capacity and re-
sources such as PD nurses and therapists and the level of
demand for care in community services. In this context,
the processes of workforce planning and training pro-
grams need to be designed with current and future shifts
toward community services [40, 41].
Adequate resource availability is important to ensure
quality of the care provided in community services to
maximise impact on quality of life (5,42,43]. The inte-
gration between health services and social services is
another key driver of quality of care in Community
Services [39, 42]. As care in community services is
organised in Multidisciplinary Teams (MDT) including
PD nurses, therapists, and social services workers, it is
Table 4 Average, 95% lower and upper CI results for the level of activity of PD doctors and nurses
Performance Indicator Baseline Scenario 1: Low
use of CS
Scenario 2: Medium
Use of CS
Scenario 3: High
Use of CS
Scenario 4: Very
High Use of CS
PD doctors service hours 8225 (7978, 8554) 7494 (7344, 7719) 7158 (6800, 7444) 6537 (6210, 6995) 5873 (5579, 6108)
PD nurses service hours 10357 (10150, 10978) 9854 (9460,10347) 9553 (8884, 10222) 8831 (8301, 9449) 8016 (7776, 8256)
PD doctors total FTEs 1.07 (0.995, 1.123) 0.97 (0.950,1.028) 0.93 (0.892, 0.985) 0.85 (0.824,0.884) 0.76 (0.722, 0.782)
PD nurses total FTEs 3.4 (3.230, 3.502) 3.2 (2.976, 3.36) 3.1 (2.883, 3.255) 2.9 (2.726,3.016) 2.6 (2.444, 2.756)
Total FTEs 4.47 (4.225, 4.625) 4.17 (3.926,4.388) 4.03 (3.775, 4.240) 3.75 (3.550,3.900) 3.36 (3.166, 3.538)
Fig. 5 Expected number of community services visits
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critical that the mix of resources to constitute the MDT
are available and that the MDT functions in a coherent
way to meet the multiple needs of PD patients. This
requires high levels of coordination between health and
social services in terms of the management of care plans
for patients, provision of services in a timely manner, and
the planning of workforce development and training activ-
ities. PD nurses fulfil a pivotal role as part of the MDTand
in promoting up take of community services at periodical
meetings with patients where treatment needs and care
plans are discussed [39, 43].
To ensure equity of access, health service commis-
sioners would need to review disparities in community
provision between urban and rural areas across the UK.
The findings of the research are based on results ob-
tained from the application of the DES model to a single
(albeit large) Trust in the UK. It is expected that the
general findings regarding the positive impact of increased
use of community services may be generalised to other
Trusts of various sizes in the UK. The model developed
reflects the patients’ pathways recommended by policy
documents in the UK such as NICE guidelines [5] and
which were confirmed to be relevant and practicable by
PDNSA nurses in the Trust. Cost data were from the
Department of Health and not expected to vary widely in
different Trusts. However, it is possible that the “optimal”
fraction of patients to be shifted to community services
(40% in the Trust studied in the current research) is
different in other Trusts due to varying patient numbers
and distribution of patients between the four stages of the
disease. The methodology and model is easily transferable
to other contexts, as variables are explicit and variation
can be accounted for, generating new optimal service con-
figuration. Where Trusts operate a significantly different
patient pathway and/or community services are unable to
provide the full range of services, the current model would
require significant revision.
The model was developed with the active engagement
of policy makers and staff involved in the provision of
PD treatment and care. This collaborative effort led to a
feeling of problem ownership by the stakeholders and
was a critical factor in the adoption of the model and its
results. This positive outcome was also facilitated by de-
velopments in user friendly Simulation software, lower-
ing the technical barriers faced by health managers and
enabling them to play a more assertive role in building
and using simulation models. The current study reflects
well this evolutionary process and the move from the
Table 6 Average, 95% lower and upper CI results for community services and total PD treatment costs
Performance
Indicator
Baseline Scenario 1: Low
use of CS
Scenario 2: Medium
Use of CS
Scenario 3: High
Use of CS
Scenario 4: Very
High Use of CS
Physiotherapy
cost
135,052
(126,949, 140,454)
140,600
(133,570, 150,442)
153,368
(145,700; 159,503)
178,904
(171,748; 191,427)
256,690
(243,856; 272,091)
SLT cost 322,272
(306,158; 341,608)
335,424
(322,007; 348,841)
365,856
(354,880; 391,466)
426,912
(405,566; 456,796)
612,384
(581,765; 655,251)
Psychiatry cost 88,800
(85,248; 92,352)
92,500
(86,950; 97,125)
100,950
(96,912; 105,998)
117,750
(110,685; 123,638)
168,900
(158,766; 180,723)
Occupational
therapy cost
135,430
(130,013; 144,910)
140,360
(136,149; 147,378)
153,120
(143,933; 162,307)
178,582
(171,439; 185,725)
240,700
(228,665; 250,328)
Palliative care
cost
22,700
(21,792; 24,062)
23,850
(22,419; 25,520)
25,950
(24,393; 27,248)
30,300
(29,391; 32,421)
36,550
(35,088; 38,012)
Dietician cost 21,700
(20,832; 23,219)
22,700
(21,338; 23,835)
24,800
(23,808; 25,792)
28,950
(27,792; 30,108)
40,900
(38,855; 43,354)
Total community
services Costs
725,954
(690,992, 766,605)
755,434
(722,433, 793,141)
824,044
(789,626, 872,314)
961,398
(916,621, 1,020,115)
1,356,124
(1,286,995, 1,439,759)
Total PD
treatment Costs
4,089,004
(3,953,151, 4,310,784)
3,882,214
(3,691,168, 4,091,041)
3,831,754
(3,691,358, 4,031,828)
3,724,188
(3,541,272, 3,922,179)
3,850,584
(3,643,811, 4,058,045)
Table 5 Average, 95% lower and upper CI results for hospital costs
Performance
Indicator
Baseline Scenario 1: Low
use of CS
Scenario 2:
Medium Use of CS
Scenario 3:
High Use of CS
Scenario 4: Very
High Use of CS
PD doctors
cost
1,809,500
(1,755,215; 1,881,880)
1,648,680
(1,549,759; 1,731,114)
1,574,760
(1,511,770; 1,669,246)
1,438,140
(1,366,233; 1,524,428)
1,292,060
(1,214,536; 1,343,742)
PD nurses
cost
1,553,550
(1,506,944; 1,662,299)
1,478,100
(1,418,976; 1,566,786)
1,432,950
(1,389,962; 1,490,268)
1,324,650
(1,258,418; 1,377,636)
1,202,400
(1,142,280; 1,274,544)
Total
Hospital Costs
3,363,050
(3,262,159, 3,544,179)
3,126,780
(2,968,735, 3,297,900)
3,007,710
(2,901,732, 3,159,514)
2,762,790
(2,624,651, 2,902,064)
2,494,460
(2,356,816, 2,618,286)
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times when model building was the sole responsibility of
technical experts to the current contexts where this re-
sponsibility is shared by the problem owners and the
modellers [44].
The current study also highlights the growing role
Simulation modelling is playing in the context of the
shift towards more “evidence based” decision making in
the health sector. It has been observed that in several
instances, health managers had a clear idea about the deci-
sions to be made to improve performance, but lacked the
evidence to make a case to decision makers. By providing
that evidence, simulation modelling fills this gap and al-
lows policies to be selected and implemented with confi-
dence and with a clear vision about what is expected in
the future.
The study, of course, has some limitations. The model
represented a single Trust and this has implications for
generalizability of the results as discussed earlier. The
model did not take account of the psychological attri-
butes of the patients and how these could influence the
progression of the disease and the effectiveness of the
treatment. Furthermore, as it is virtually impossible to
wholly represent real world complexity of health systems
[23], the results of this study should be interpreted with
care. The model includes a number of assumptions and
simplifications, and increased complexity would be in-
troduced by: the different age categories of patients; co-
existence of other medical conditions in addition to PD
for some patients; socio-economic status of patients; ef-
fects of syndromes such as lack of mobility, depression,
and dementia on attendance of planned appointments in
hospitals and community services. Opportunity costs to pa-
tients and indeed carers are important but outside the
scope of this current study. Future research and model de-
velopment which integrates both the provider and patients’
perspectives are needed.
Conclusions
The number of patients affected by PD is increasing and
this trend is expected to continue and magnify in line
with the UK population structure and ageing. This creates
significant pressures on PD and wider services in the
absence of a cure. Current evidence suggests that treatment
of degenerative neurological diseases such as PD is expen-
sive, inefficient, inaccessible to a considerable number of
patients, and of sub-optimal quality. Financial austerity and
cuts to public funds allocated to the health sector demand
innovative solutions for care delivery leading to efficiencies
across a healthcare economy. The current study is particu-
larly timely against this background and explores the possi-
bility and scale of efficiency gains, which could be achieved
if Community Services are more widely adopted and be-
come an integrated part of the PD treatment process.
In terms of policy, current PD treatment and patient
management guidelines and procedures are a decade
old, and may no longer be appropriate in the current
NHS environment. The formal evaluation of innovative
treatment procedures such as the use of community
services could offer policy makers insights about more
effective ways of caring for PD patients whilst enhancing
Fig. 6 Expected hospital costs, community services costs, and total PD treatment costs
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quality. The advantages of community services need to
be effectively shared with PD patients and carers to help
inform management choices and care plans.
The successful application of Simulation Modelling in
this research and the enthusiasm and engagement of key
participants strengthens the argument for co-developing
policy improvement. As the complexity of health systems
increases in an environment of constrained resources, so
too does the need for evidence based decision making.
Simulation modelling is well positioned to provide that evi-
dence and allow policy makers to face upcoming challenges
with greater confidence.
Additional file
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